循环肿瘤DNA中的核小体模式揭示晚期前列腺癌表型的转录调控
研究对来自患者来源异种移植瘤(涵盖雄激素受体活性(ARPC)和神经内分泌(NEPC)前列腺癌谱系)的血浆ctDNA进行全基因组测序,分析核小体定位模式。基于ctDNA中关键转录调控因子活性构建的预测模型,区分主导表型的准确率为97%,混合临床表型的准确率为87%。
要点
- ctDNA核小体模式可反映基因、启动子、组蛋白修饰和转录因子结合等区域的转录活性。
- 从ctDNA中可识别AR、ASCL1、HOXB13、HNF4G和GATA2等表型定义性转录调控因子的活性。
- 预测模型区分NEPC与ARPC的准确率为主导表型97%、混合临床表型87%。
核心结论
- ctDNA可提供与肿瘤活检IHC或转录组分析相当的晚期前列腺癌表型分类结果,对精准肿瘤学具有诊断优势。
研究设计与样本
- 研究对来自患者来源异种移植瘤(涵盖ARPC和NEPC前列腺癌谱系)的血浆ctDNA进行全基因组测序,分析核小体定位模式。
主要发现
- 与转录活性相关的核小体模式在ctDNA中体现于基因、启动子、组蛋白修饰、转录因子结合和可及染色质区域。
- 从ctDNA中识别出AR、ASCL1、HOXB13、HNF4G和GATA2等关键表型定义性转录调控因子的活性。
- 为区分患者血浆样本中的NEPC和ARPC,开发的预测模型准确率为主导表型97%、混合临床表型87%。
临床怎么用
- 作者证明ctDNA可提供与肿瘤活检IHC或转录组分析相当的晚期前列腺癌表型分类结果,对精准肿瘤学具有诊断优势。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Advanced prostate cancers comprise distinct phenotypes, but tumor classification remains clinically challenging. Here, we harnessed circulating tumor DNA (ctDNA) to study tumor phenotypes by ascertaining nucleosome positioning patterns associated with transcription regulation. We sequenced plasma ctDNA whole genomes from patient-derived xenografts representing a spectrum of androgen receptor active (ARPC) and neuroendocrine (NEPC) prostate cancers. Nucleosome patterns associated with transcriptional activity were reflected in ctDNA at regions of genes, promoters, histone modifications, transcription factor binding, and accessible chromatin. We identified the activity of key phenotype-defining transcriptional regulators from ctDNA, including AR, ASCL1, HOXB13, HNF4G, and GATA2. To distinguish NEPC and ARPC in patient plasma samples, we developed prediction models that achieved accuracies of 97% for dominant phenotypes and 87% for mixed clinical phenotypes. Although phenotype classification is typically assessed by IHC or transcriptome profiling from tumor biopsies, we demonstrate that ctDNA provides comparable results with diagnostic advantages for precision oncology. SIGNIFICANCE: This study provides insights into the dynamics of nucleosome positioning and gene regulation associated with cancer phenotypes that can be ascertained from ctDNA. New methods for classification in phenotype mixtures extend the utility of ctDNA beyond assessments of somatic DNA alterations with important implications for molecular classification and precision oncology. This article is highlighted in the In This Issue feature, p. 517.
引用
- De Sarkar N, Patton RD, Doebley AL, et al. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes. Cancer Discov. 2023. PMID: 36399432. doi:10.1158/2159-8290.CD-22-0692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。